Earlier this month, a study of a much-watched cell therapy that genetically modifies patients’ immune cells in order to attack tumors was stopped because the treatment may have caused the deaths of two patients. The trial is now once again enrolling patients, according to Juno Therapeutics, the startup that is commercializing the treatment. Juno has raised $145 million from investors including Jeff Bezos to develop cancer-fighting cell therapies and is in a race to market with Novartis NVS +0.31%, which made a big bet on a similar technology developed at the University of Pennsylvania, as well as other efforts from Kite Pharma and the team of Bluebird and Celgene CELG -0.23%.
Help employers find you! Check out all the jobs and post your resume.
